A group of Israeli researchers has launched a Phase II study of a drug that they believe could keep patients off mechanical ventilation and speed their recovery. The trial, which is being collectively run by Ziv and Rambam medical centers with researchers from Bar-Ilan University and Technion-Israel Institute of Technology, is examining the use of a drug based on a naturally occurring peptide called angiotensin 1-7 to help counter the impact of COVID-19 on the lungs. Read More